Study compares apomorphine and ropinirole for canine emesis

A newly published study is adding timely evidence to a common toxicology and urgent-care decision in small animal practice: whether to reach for apomorphine or ropinirole when a dog needs emesis induced. In the 2025 Frontiers in Veterinary Science paper, researchers concluded that ophthalmic ropinirole was as effective as intravenous apomorphine in healthy dogs, although apomorphine produced vomiting much faster. (frontiersin.org)

That question matters because the two drugs occupy different places in practice. Apomorphine has long been a mainstay emetic in dogs, typically used extra-label by IV, conjunctival, SC, IM, or oral routes, depending on formulation and setting. Ropinirole, approved by the FDA in June 2020 as Clevor, introduced the first labeled canine emetic in an ophthalmic, single-use format. Its arrival gave clinics an on-label alternative that doesn’t require compounding or injection, which has obvious implications for stocking, handling, and team workflow. (fda.gov)

In the new crossover trial, 24 healthy dogs received both treatments in a blinded, randomized design. Success rates were high for both drugs, 95.8% for apomorphine and 100% for ropinirole, and repeat dosing was needed in 25% of the apomorphine group versus 8.3% of the ropinirole group. But onset was meaningfully different: median time to emesis was 1.18 minutes with apomorphine and 8.85 minutes with ropinirole. Investigators also reported similar overall adverse event rates, with more ocular redness and more protracted vomiting in the ropinirole group. (frontiersin.org)

Those findings line up partly, but not completely, with earlier data. In the FDA field study supporting Clevor’s approval, 94 of 99 treated dogs vomited within 30 minutes, and 85 of those dogs vomited within 20 minutes without requiring a second dose; mean time to first vomition was 12 minutes. The label also highlights expected adverse effects including conjunctival hyperemia, third-eyelid protrusion, lethargy, salivation, tremors, transient tachycardia, and prolonged vomiting. The product is indicated only for dogs, should be administered by veterinary personnel, and has not been fully evaluated in dogs under 4.5 months of age, under 4 pounds, or in dogs with hepatic impairment, pregnancy, lactation, or breeding intent. (vetoquinolusa.com)

Practice-oriented reviews have framed the comparison in similarly pragmatic terms. The University of Illinois College of Veterinary Medicine notes that apomorphine remains extra-label in the U.S. and may be faster, especially IV, while ropinirole offers FDA approval and ocular administration. VetGirl’s review of the 2025 Journal of Veterinary Emergency and Critical Care study adds useful real-world context: that trial prospectively randomized 132 client-owned dogs at two specialty referral hospitals from October 2021 through March 2023 after suspected or confirmed toxin or foreign-body ingestion. Dogs were excluded if they were under 4.5 months old, weighed less than 1.8 kg, had ocular, CNS, or hepatic disease, had ingested material for which emesis was contraindicated, or had already received antiemetics. Ingestions included toxic foods such as xylitol, chocolate, and grapes or raisins; plants; medications; rodenticides and other poisons; and foreign material ranging from toys and cords to cloth items. Dogs that did not vomit within 20 minutes received a second identical dose, were monitored for 40 minutes, and could receive rescue antiemetics after successful emesis. Today’s Veterinary Practice also emphasizes that emesis is not interchangeable across all poisonings or patients: it should be avoided with caustics, petroleum distillates, or in animals already showing neurologic signs or significant aspiration risk. That context is important, because the choice of emetic is only one part of decontamination, not the whole plan. (vetmed.illinois.edu)

There’s also a note of caution from emerging real-world evidence. A 2025 abstract indexed in PubMed, based on that emergency-setting population, reported that ropinirole had lower first-dose success, slower time to first emetic event, and more minor adverse effects and protracted vomiting requiring rescue therapy than IV apomorphine. VetGirl’s summary adds that rescue protocols in the study used maropitant at 1 mg/kg IV after apomorphine and metoclopramide at 0.4 mg/kg IV following ropinirole. Because that report reflects an emergency population rather than healthy research dogs, it suggests the setting and case mix may meaningfully affect how these drugs compare in practice. That’s an inference, but it’s a reasonable one based on the available sources. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, this isn’t a story about one drug clearly replacing the other. It’s about better matching the emetic to the case. If a dog is stable, IV access is available, and speed is critical, apomorphine may still be the more efficient choice. If a clinic values labeled use, simpler stocking, and needle-free administration, ropinirole has a strong case, especially given its high efficacy and single-use packaging. Teams also need to weigh human handling precautions, the possibility of ocular irritation, the risk of prolonged vomiting, and whether antiemetic rescue may be needed after successful decontamination. Supportive care options may also get easier to manage soon: Dechra says its newly FDA-approved Emeprev injectable, a bioequivalent maropitant product for dogs and cats, will launch through major veterinary distributors in early 2026. The company says the product does not require refrigeration and includes benzyl alcohol, which reduced injection discomfort in dogs in company-cited studies, potentially making post-emesis antiemetic care a bit more workflow-friendly.

What to watch: The next development to watch is whether more comparative data emerge from emergency and general-practice populations, not just healthy dogs, and whether those findings shift clinic protocols on first-line emetic selection, especially in toxicology workflows where minutes, staffing, and follow-up care all matter. It’s also worth watching whether newer antiemetic products such as Emeprev change how clinics approach rescue therapy and vomiting management after decontamination, particularly if easier storage and lower injection pain translate into practical uptake. (pubmed.ncbi.nlm.nih.gov)